Literature DB >> 3169110

Studies of the agonist and antagonist activity of cicloprolol in man.

P M McCaffrey1, M Burke, J G Riddell, R G Shanks.   

Abstract

To assess the partial agonist activity of cicloprolol in man, four studies were carried out in normal male volunteers. I and II. Open dose escalating studies of the effects of oral doses of the drug on exercise tachycardia and sleeping heart rate. III and IV. Double-blind randomized studies of the effects of placebo, cicloprolol 25 mg, cicloprolol 50 mg, cicloprolol 100 mg, atenolol 50 mg, pindolol 10 mg, salbutamol 8 mg and prenalterol 50 mg on sleeping heart rate, resting supine heart rate, blood pressure, forearm blood flow, finger tremor and exercise tachycardia. All doses of cicloprolol above 2.5 mg reduced an exercise tachycardia but there was no increase in effect above a dose of 50 mg. Cicloprolol caused a dose dependent increase in sleeping heart rate up to 200 mg. Cicloprolol increased resting supine heart rate, systolic blood pressure, forearm blood flow and finger tremor. None of the drugs affected quality of sleep. Cicloprolol has significant partial agonist activity at the beta 1-adrenoceptor as indicated by increases in heart rate and systolic blood pressure. The increases in finger tremor and forearm blood flow suggest that cicloprolol has some partial agonist activity at the beta 2-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3169110     DOI: 10.1007/bf00615219

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  On the nature of normal tremor.

Authors:  J BRUMLIK
Journal:  Neurology       Date:  1962-03       Impact factor: 9.910

2.  New class of selective stimulants of beta-adrenergic receptors.

Authors:  D Hartley; D Jack; L H Lunts; A C Ritchie
Journal:  Nature       Date:  1968-08-24       Impact factor: 49.962

3.  The role of the ballistocardiac impulse in the genesis of physiological tremor.

Authors:  C D Marsden; J C Meadows; G W Lange; R S Watson
Journal:  Brain       Date:  1969       Impact factor: 13.501

4.  The regulation of heart rate during sleep.

Authors:  W Baust; B Bohnert
Journal:  Exp Brain Res       Date:  1969       Impact factor: 1.972

5.  Basic pharmacological properties of prenalterol.

Authors:  H Mattsson; A Hedberg; E Carlsson
Journal:  Acta Med Scand Suppl       Date:  1982

6.  Sleep studies in clinical pharmacology.

Authors:  I Oswald
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

7.  The St. Mary's Hospital sleep questionnaire: a study of reliability.

Authors:  B W Ellis; M W Johns; R Lancaster; P Raptopoulos; N Angelopoulos; R G Priest
Journal:  Sleep       Date:  1981       Impact factor: 5.849

8.  A study of the relationship between cardiac beta-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines.

Authors:  A Bilski; H H Robertson; J L Wale
Journal:  Clin Exp Pharmacol Physiol       Date:  1979 Jan-Feb       Impact factor: 2.557

9.  Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.

Authors:  P E Hicks; I Cavero; P Manoury; F Lefevre-Borg; S Z Langer
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

10.  beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol.

Authors:  H Mattsson; T Andersson; E Carlsson; A Hedberg; B Lundgren; T Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

View more
  2 in total

1.  Pharmacokinetics and safety of cicloprolol in uraemic patients.

Authors:  J P Fillastre; M Aparicio; C Porquet; C Dubruc; P Rosenzweig; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

2.  Pharmacodynamic without pharmacokinetic interaction between cicloprolol, a partial beta 1-adrenoceptor agonist, and digoxin in healthy subjects.

Authors:  S Weber; A Kahan; J L Pinquier; J Julien; P Rosenzweig; G Bianchetti; P L Morselli; O Dessault; D De Lauture; G Strauch
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.